Teleflex Incorporated announces that it has received 510(k) market clearance from the Food and Drug Administration (FDA) for the company’s ArrowEVOLUTION™ PICC with Chlorag+ard™ technology, a peripherally inserted central catheter with a chlorhexedine-based solution that has been chemically bonded into the surface of the catheter both intra- and extralumenally. Teleflex will launch the product for general availability in the United States in the fourth quarter.
"Market clearance from FDA for the ArrowEVOLUTION PICC with Chlorag+ard technology represents another significant milestone for Teleflex as we continue to provide innovative technologies to support healthcare providers who are working to improve patient outcomes through infection prevention,” says Jeff Black, Teleflex chairman and CEO. "We believe the ArrowEVOLUTION PICC with its anti-microbial coating will provide a technological advancement and unique option to clinicians in their efforts to protect against central line-associated bloodstream infections, a major contributor to hospital-acquired infections.”
Through its Arrow brand, Teleflex is one of the leading global providers of vascular access technology with a commitment to helping healthcare providers in their efforts toward attaining and sustaining zero central line-associated bloodstream infections. The Arrow family of products also includes ARROWg+ard Blue PLUS® acute central venous catheters with a chlorhexedine-based technology and maximal barrier precautions trays designed to support compliance with practice recommendations and guidelines.